Publication: Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation
Issued Date
2017-01-01
Resource Type
ISSN
10982825
08878013
08878013
Other identifier(s)
2-s2.0-84994175817
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Laboratory Analysis. Vol.31, No.1 (2017)
Suggested Citation
Santirat Prommas, Apichaya Puangpetch, Nuttawut Jenjirattithigarn, Sumonrat Chuwongwattana, Thawinee Jantararoungtong, Napatrupron Koomdee, Siwalee Santon, Montri Chamnanphon, Chonlaphat Sukasem Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation. Journal of Clinical Laboratory Analysis. Vol.31, No.1 (2017). doi:10.1002/jcla.22011 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42013
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation
Other Contributor(s)
Abstract
© 2016 Wiley Periodicals, Inc. Background: Voriconazole (VRZ) is a triazole antifungal used for treatment of invasive fungal infection, which is a life-threatening condition. Therapeutic drug monitoring is recommended for identifying the optimal dose in patients who have hepatic/renal impairment or reduced function of the CYP2C19 metabolizing enzyme. Methods: One hundred microliters of sample plasma was extracted by protein precipitated with 200 μl of acetonitrile containing fluconazole as internal standard (IS). After vortexing and centrifugation, supernatant was dried and reconstituted with 100 μl of mobile phase (ACN: 0.1% formic acid in 10 mM Ammonium acetate) (50:50 v/v) before injected. The column was C18, 2.7 μm, 3.0 × 50 mm at flow rate of 0.5 ml/min with retention time of 0.5 and 0.75 min for VRZ and IS, respectively. The tandem mass spectrometer was set in multiple reactions monitoring (MRM) mode with the following transition; VRZ m/z 350.10→281.10 and 307.20→220.20 (IS). Results: The accuracy and precision inter- and intra-day were less than 9%, over the range 0.05–10 μg/ml. The linearity was consistent (r2 = 0.9987) and recovery was more than 85.0% for both analyses. Conclusion: This method is applicable for routine monitoring of patients’ VRZ plasma level with fast and accurate runtime to assess CYP2C19 genotype.